Ara es mostren 10401 - 10420 de 15316 resultats
Resistance to CD19-CAR-T cells in hematologic malignancies can appear linked to loss or downregulation of CD19 expression or an immunosuppressive t...
The progress of CAR-T cells is limited by a poor understanding of how the design and signaling of these CAR proteins affect T cell efficacy and per...
While T-cell based immunotherapies have revolutionized cancer treatment, a majority of patients fail to respond or relapse after a certain period o...
New digital technologies have opened a wide range of opportunities and challenges in the mental health field. During the last decade, our team have...
To evaluate clinical and molecular features that may condition disease onset, severity, evolution and co-morbidities. Description of the natural hi...
The strategic objective of this research line is to investigate the genetic, anatomopathological and biochemical bases, as well as the physiopathol...
To search for the physiopatological bases of these diseases we use a combination of the classical and advanced omics technologies (metabolomics, pr...
To confirm the pathogenicity of a certain gene or molecular mechanism, we validate cell models derived from patient to study the disease. We use fi...
This line involves the testing of chemical and peptide libraries, as well as genetic edition strategies. Selection has been made on disease-causing...
Ras proteins are GTPases that regulate signal transduction pathways, which control cell proliferation, differentiation, survival and apoptosis. K-R...
The endolysosomal (LE/Lys) compartment is the main intracellular reservoir of cholesterol and acts as a sorting center from which cholesterol is de...
Led by Dr. J. Montero. The Montero Lab studies cell death, senescence and cancer precision medicine at the University of Barcelona's Department o...
Led by C. Mauvezin. Genomic instability is a hallmark of tumor cells, resulting from errors in mitotic progression such as prolonged mitosis, DNA...
Our scientific contributions to advancing knowledge in liver cancer during the last 15 years are summarized as follows: we contributed to the class...
The group contributed to the molecular classification of HCC (Hoshida, NEJM 2008, Chiang Cancer Research 2008) and to the generation of gene signat...
We developed an 11-gene signature able to predict response to immune checkpoint inhibitors in HCC (Haber Gastroenterology 2022). We also contribute...
We have molecularly characterized human NASH-HCC at the genomic and molecular levels (Pinyol Journal of Hepatology 2021).
Several studies led to the identification of Akt/mTOR pathway [Villanueva Gastroenterology, 2008), EGFR pathway (Keng, Nature Biotech 2009), IGF pa...
Gene-set (three genes) based diagnosis of HCC reported in Llovet, Gastroenterology 2006, and included in EASL-EORTC guidelines. In addition, we pro...
We have contributed to the molecular classification of iCCA (Sia, Gastroenterology 2013) and eCCA (Montal, Journal of Hepatology 2020). We identi...